Janusz Kloczko
Overview
Explore the profile of Janusz Kloczko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bolkun L, Pienkowski T, Sieminska J, Godzien J, Pietrowska K, Kloczko J, et al.
Sci Rep
. 2023 Dec;
13(1):21809.
PMID: 38071228
The heterogeneity of acute myeloid leukemia (AML), a complex hematological malignancy, is caused by mutations in myeloid cells affecting their differentiation and proliferation. Thus, various cytogenetic alterations in AML cells...
2.
Tyczynska A, Krzempek M, Cortez A, Jurczyszyn A, Godlewska K, Ciepluch H, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444579
Fragility scales are intended to help in therapeutic decisions. Here, we asked if the fragility assessment in MM patients ≥ 75 years old qualified for treatment by the local physician...
3.
Sacha T, Szczepanek E, Dumnicka P, Gora-Tybor J, Niesiobedzka-Krezel J, Prejzner W, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Dec;
22(6):405-415.
PMID: 34933827
Introduction: Tyrosine kinase inhibitors (TKIs) have greatly improved the treatment outcome for most patients with chronic myeloid leukemia (CML). Ponatinib is a new pan-inhibitor of TK active in resistant CML....
4.
Dimopoulos M, Garcia Sanz R, Lee H, Trneny M, Varettoni M, Opat S, et al.
Blood Adv
. 2020 Dec;
4(23):6009-6018.
PMID: 33284944
Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the MYD88 gene (MYD88WT) have demonstrated relatively poor outcomes to ibrutinib monotherapy, with no major responses reported in a phase 2...
5.
Breczko W, Lemancewicz D, Dzieciol J, Kloczko J, Bolkun L
Adv Med Sci
. 2020 Nov;
66(1):21-27.
PMID: 33246214
Purpose: Proteasome inhibitors (PI) bortezomib or carfilzomib among them, play a crucial role in the modern standard therapy for multiple myeloma (MM). In this study, we intended to evaluate whether...
6.
Offner F, Robak T, Janssens A, Govind Babu K, Kloczko J, Grosicki S, et al.
Br J Haematol
. 2020 Apr;
190(5):736-740.
PMID: 32236950
The Complement 1 trial investigated the efficacy and safety of ofatumumab + chlorambucil with chlorambucil monotherapy in patients with previously untreated chronic lymphocytic leukaemia (CLL). On long-term follow-up in the...
7.
Grosicki S, Lech-Maranda E, Govind Babu K, Rybka J, Litvinskaya E, Loscertales J, et al.
Leuk Lymphoma
. 2020 Feb;
61(7):1748-1751.
PMID: 32107948
No abstract available.
8.
Pluta A, Robak T, Brzozowski K, Stepka K, Wawrzyniak E, Krawczynska A, et al.
Leuk Lymphoma
. 2019 Oct;
61(3):588-603.
PMID: 31661339
We present the results of a prospective, non-randomized phase 2 trial in which 253 AML patients (pts) under 60 years old received DAC (Daunorubicin + AraC + Cladribine) as first...
9.
Gisslinger H, Buxhofer-Ausch V, Hodisch J, Radinoff A, Karyagina E, Kyrcz-Krzemien S, et al.
Br J Haematol
. 2019 Mar;
185(4):691-700.
PMID: 30919941
Anagrelide is an established treatment option for essential thrombocythaemia (ET). A prolonged release formulation was developed with the aim of reducing dosing frequency and improving tolerability, without diminishing efficacy. This...
10.
Sellers Z, Bolkun L, Kloczko J, Wojtaszewska M, Lewandowski K, Moniuszko M, et al.
Clin Epigenetics
. 2019 Mar;
11(1):50.
PMID: 30876483
Background: The delta-like non-canonical Notch ligand 1 (DLK1)-maternally expressed 3(MEG3) locus (DLK1-MEG3 locus) plays a critical role in the maintenance and differentiation of hematopoietic stem cells. Accumulating evidence implicates the...